<DOC>
	<DOCNO>NCT02347176</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety tralokinumab adult atopic dermatitis</brief_summary>
	<brief_title>Phase 2 Study Evaluate Efficacy Safety Tralokinumab Adults With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Physician diagnosis atopic dermatitis &gt; 1 year Atopic dermatitis involvement ≥ 10 % body surface area EASI score ≥ 12 SCORAD ≥ 25 IGA score ≥ 3 Effective birth control line protocol detail History anaphylaxis follow biologic therapy Hepatitis B , C HIV Pregnant breastfeed History cancer Previous receipt tralokinumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>